Amplia Therapeutics

Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer.

FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Contact Details

Level 29, 55 Collins Street , MELBOURNE VIC 3000

02 8003 3650

info@ampliatx.com

www.ampliatx.com

Lists and Charts

Share price

Amplia Therapeutics
Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 02/12/24

Rank	Company	1 Yr	5 Yr
514^th	Bell Financial Group	23.2%	11.87%
515^th	Bell Potter Securities	23.2%	11.87%
516^th	Amplia Therapeutics	23.16%	4.76%
517^th	Evans & Partners Asia Fund	22.83%	0%
518^th	Neurotech International	22.74%	34.61%

View Full List

1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Jane Bell, Non-Executive Director	19 Apr 2021
	NEW ROLE: Robert Peach, Non-Executive Director	19 Apr 2021
	NEW ROLE: Jeff Carter, CEO and Managing Director	24 Nov 2020
	NEW ROLE: Janette Dixon,	24 Nov 2020
	NEW ROLE: Gill Webster,	24 Nov 2020
	NEW ROLE: Andrew Cooke, Company Secretary	03 Nov 2020
	NEW ROLE: John Lambert, Chief Executive, Managing Director since 2020	03 Nov 2020
	NEW ROLE: Colin Boyan, Non-Executive Director	03 Nov 2020

Related Information

Access to our data for Amplia Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Amplia Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today